1%聚桂醇注射治療血管瘤血管畸形的Meta分析
發(fā)布時間：2019-01-18 12:13
【摘要】：目的本研究旨在通過Meta分析探討1%聚桂醇瘤體內(nèi)注射治療血管瘤及血管畸形的有效性及安全性,進(jìn)一步明確聚桂醇的治療作用,為臨床合理藥物治療提供循證醫(yī)學(xué)證據(jù)。方法按Cochrane系統(tǒng)評價方法,檢索Pub Med(建庫-2014.12)、Cochrane(建庫-2014.12)、Science Direct(SDOS)(建庫-2014.12)、相關(guān)期刊論文CNKI(1979-2014.12)、重慶維普中文科技期刊數(shù)據(jù)庫VIP(1989-2014.12)、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫CBM(1978-2014.12)、萬方數(shù)據(jù)庫(1998-2014.12),語種限中文和英文,納入已發(fā)表的與聚桂醇注射治療血管瘤血管畸形相關(guān)的臨床隨機(jī)對照試驗(yàn)的文獻(xiàn),提取有效數(shù)據(jù)(有效率、復(fù)發(fā)率、不良反應(yīng)發(fā)生率),并對提取的數(shù)據(jù)用Cochrane協(xié)作網(wǎng)提供的Rev Man5.2軟件進(jìn)行統(tǒng)計,計算比值比(OR)和95%置信區(qū)間(95%CI);如果各項研究存在異質(zhì)性,分析數(shù)據(jù)采用隨機(jī)效應(yīng)模型進(jìn)行,如果各項研究不存在異質(zhì)性或異質(zhì)性低,則采用固定效應(yīng)模型進(jìn)行;發(fā)表性偏倚用倒漏斗圖分析表示;必要時為檢驗(yàn)結(jié)果的穩(wěn)定性可懫用敏感性分析。結(jié)果最終共有19篇文獻(xiàn),包含19項臨床對照試驗(yàn)(1768個病例)被納入。采用Rev Man5.2軟件進(jìn)行統(tǒng)計分析結(jié)果為:聚桂醇治療血管瘤及血管畸形的有效率與無水乙醇相比差異無統(tǒng)計學(xué)意義(OR=0.34,95%CI:0.05-2.30,P=0.27),不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(OR=0.33,95%CI:0.14-0.80,P=0.01);聚桂醇治療血管瘤及血管畸形的有效率與平陽霉素相比差異無統(tǒng)計學(xué)意義(OR=0.92,95%CI:0.39-2.16,P=0.85),不良反應(yīng)發(fā)生率低于平陽霉素(OR=0.20,95%CI:0.07-0.58,P=0.003);聚桂醇治療血管瘤及血管畸形的有效率與介入治療相比差異無統(tǒng)計學(xué)意義(OR=2.01,95%CI:0.85-4.75,P=0.11),不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(OR=0.29,95%CI:0.09-0.97,P=0.04);聚桂醇治療血管瘤血管畸形的有效率與激素和普萘洛爾相比差異無統(tǒng)計學(xué)意義(OR=2.65,95%CI:0.85-8.31,P=0.09),不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(OR=0.88,95%CI:0.14-5.57,P=0.89);聚桂醇治療血管瘤血管畸形的有效率與乙醇胺相比差異無統(tǒng)計學(xué)意義(OR=1.49,95%CI:0.12-18.68,P=0.76),不良反應(yīng)發(fā)生率差異亦無統(tǒng)計學(xué)意義(OR=1.30,95%CI:0.08-21.90,P=0.86);泡沫型聚桂醇治療血管瘤血管畸形的有效率與液體型相比差異有統(tǒng)計學(xué)意義(RR=1.84,95%CI:1.25-2.72,P=0.002),不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(OR=0.35,95%CI:0.10-1.19,P=0.09);1%聚桂醇治療血管瘤血管畸形的有效率與3%聚桂醇相比差異有統(tǒng)計學(xué)意義(OR=0.47,95%CI:0.25-0.88,P=0.02),不良反應(yīng)發(fā)生率差異無統(tǒng)計學(xué)意義(OR=0.46,95%CI:0.22-0.96,P=0.04)。結(jié)論Meta分析的結(jié)果表明,對于血管瘤血管畸形的治療,聚桂醇的療效療與其他治療方法相比無顯著優(yōu)勢,但其不良反應(yīng)發(fā)生率低,是一種安全有效的治療方法。
[Abstract]:Objective to investigate the efficacy and safety of intratumoral injection of 1% polycinnamol in the treatment of hemangioma and vascular malformation by Meta analysis. Methods according to the evaluation method of Cochrane system, we searched the Pub Med (database-2014.12), Cochrane (database-2014.12), Science Direct (SDOS) (database-2014.12) and the Chinese periodical full-text database CNKI (1979-2014.12). VIP (1989-2014.12), CBM (1978-2014.12), Wanfang (1998-2014.12), limited to Chinese and English, To include published literature on clinical randomized controlled trials related to the injection of polycinnamol in the treatment of hemangioma vascular malformation, and to extract effective data (effective rate, recurrence rate, incidence of adverse reactions), The extracted data are counted by Rev Man5.2 software provided by Cochrane cooperation network, and the ratio is calculated by (OR) and 95% confidence interval (95%CI). If heterogeneity exists in each study, random effect model is used to analyze the data, if there is no heterogeneity or heterogeneity is low in each study, fixed effect model is used, publication bias is expressed by inverted funnel graph analysis. Sensitivity analysis can be used if necessary for the stability of the test results. Results A total of 19 articles including 19 clinical controlled trials (1768 cases) were included. The results of statistical analysis with Rev Man5.2 software were as follows: the effective rate of polycinnamol in treating hemangioma and vascular malformation had no statistical significance (OR=0.34,95%CI:0.05-2.30,P=0.27) compared with anhydrous alcohol. There was no significant difference in the incidence of adverse reactions (OR=0.33,95%CI:0.14-0.80,P=0.01). There was no significant difference (OR=0.92,95%CI:0.39-2.16,P=0.85) between polycinnamol and pingyangmycin in the treatment of hemangioma and vascular malformation. The incidence of adverse reactions was lower than that of pingyangmycin (OR=0.20,95%CI:0.07-0.58,P=0.003). The effective rate of polycinnamol in treating hemangioma and vascular malformation was not significantly different from that of interventional therapy (OR=2.01,95%CI:0.85-4.75,P=0.11). There was no significant difference in the incidence of adverse reactions (OR=0.29,95%CI:0.09-0.97,P=0.04). The effective rate of polycinnamol in the treatment of hemangioma vascular malformation was not significantly different from that of hormone and propranolol (OR=2.65,95%CI:0.85-8.31,P=0.09). There was no significant difference in the incidence of adverse reactions (OR=0.88,95%CI:0.14-5.57,P=0.89). There was no significant difference (OR=1.49,95%CI:0.12-18.68,P=0.76) between polycinnamol and ethanolamine in the treatment of hemangioma vascular malformation. There was no significant difference in the incidence of adverse reactions (OR=1.30,95%CI:0.08-21.90,P=0.86). The effective rate of foam polycinnamol in the treatment of hemangioma vascular malformation was significantly different from that of liquid type (RR=1.84,95%CI:1.25-2.72,P=0.002). There was no significant difference in the incidence of adverse reactions (OR=0.35,95%CI:0.10-1.19,P=0.09). The effective rate of 1% polycinnamol in the treatment of hemangioma vascular malformation was significantly higher than that in 3% polycinnamol (OR=0.47,95%CI:0.25-0.88,P=0.02). There was no significant difference in the incidence of adverse reactions (OR=0.46,95%CI:0.22-0.96,P=0.04). Conclusion the results of Meta analysis show that polycinnamol has no significant advantage in the treatment of hemangioma vascular malformation, but its adverse reaction rate is low, so it is a safe and effective treatment method.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R654.3
本文編號：2410708
[Abstract]:Objective to investigate the efficacy and safety of intratumoral injection of 1% polycinnamol in the treatment of hemangioma and vascular malformation by Meta analysis. Methods according to the evaluation method of Cochrane system, we searched the Pub Med (database-2014.12), Cochrane (database-2014.12), Science Direct (SDOS) (database-2014.12) and the Chinese periodical full-text database CNKI (1979-2014.12). VIP (1989-2014.12), CBM (1978-2014.12), Wanfang (1998-2014.12), limited to Chinese and English, To include published literature on clinical randomized controlled trials related to the injection of polycinnamol in the treatment of hemangioma vascular malformation, and to extract effective data (effective rate, recurrence rate, incidence of adverse reactions), The extracted data are counted by Rev Man5.2 software provided by Cochrane cooperation network, and the ratio is calculated by (OR) and 95% confidence interval (95%CI). If heterogeneity exists in each study, random effect model is used to analyze the data, if there is no heterogeneity or heterogeneity is low in each study, fixed effect model is used, publication bias is expressed by inverted funnel graph analysis. Sensitivity analysis can be used if necessary for the stability of the test results. Results A total of 19 articles including 19 clinical controlled trials (1768 cases) were included. The results of statistical analysis with Rev Man5.2 software were as follows: the effective rate of polycinnamol in treating hemangioma and vascular malformation had no statistical significance (OR=0.34,95%CI:0.05-2.30,P=0.27) compared with anhydrous alcohol. There was no significant difference in the incidence of adverse reactions (OR=0.33,95%CI:0.14-0.80,P=0.01). There was no significant difference (OR=0.92,95%CI:0.39-2.16,P=0.85) between polycinnamol and pingyangmycin in the treatment of hemangioma and vascular malformation. The incidence of adverse reactions was lower than that of pingyangmycin (OR=0.20,95%CI:0.07-0.58,P=0.003). The effective rate of polycinnamol in treating hemangioma and vascular malformation was not significantly different from that of interventional therapy (OR=2.01,95%CI:0.85-4.75,P=0.11). There was no significant difference in the incidence of adverse reactions (OR=0.29,95%CI:0.09-0.97,P=0.04). The effective rate of polycinnamol in the treatment of hemangioma vascular malformation was not significantly different from that of hormone and propranolol (OR=2.65,95%CI:0.85-8.31,P=0.09). There was no significant difference in the incidence of adverse reactions (OR=0.88,95%CI:0.14-5.57,P=0.89). There was no significant difference (OR=1.49,95%CI:0.12-18.68,P=0.76) between polycinnamol and ethanolamine in the treatment of hemangioma vascular malformation. There was no significant difference in the incidence of adverse reactions (OR=1.30,95%CI:0.08-21.90,P=0.86). The effective rate of foam polycinnamol in the treatment of hemangioma vascular malformation was significantly different from that of liquid type (RR=1.84,95%CI:1.25-2.72,P=0.002). There was no significant difference in the incidence of adverse reactions (OR=0.35,95%CI:0.10-1.19,P=0.09). The effective rate of 1% polycinnamol in the treatment of hemangioma vascular malformation was significantly higher than that in 3% polycinnamol (OR=0.47,95%CI:0.25-0.88,P=0.02). There was no significant difference in the incidence of adverse reactions (OR=0.46,95%CI:0.22-0.96,P=0.04). Conclusion the results of Meta analysis show that polycinnamol has no significant advantage in the treatment of hemangioma vascular malformation, but its adverse reaction rate is low, so it is a safe and effective treatment method.
【學(xué)位授予單位】：安徽醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2015
【分類號】：R654.3
【參考文獻(xiàn)】
相關(guān)期刊論文 前1條
1 張洪濤;葉濤;;平陽霉素聯(lián)合聚桂醇治療口腔頜面部血管瘤的臨床療效評價[J];實(shí)用臨床醫(yī)藥雜志;2013年09期
，本文編號：2410708
本文鏈接：http://sikaile.net/yixuelunwen/waikelunwen/2410708.html
最近更新
教材專著
